Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lamotrigine - GlaxoSmithKline

Drug Profile

Lamotrigine - GlaxoSmithKline

Alternative Names: 430C78; BW 430C; Labileno; Lamactil; Lamictal; Lamictin; Lamitrin

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Antiepileptic drugs; Mood stabilisers; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
  • No development reported Absence epilepsy
  • Discontinued Diabetic neuropathies; Neuropathic pain; Schizophrenia

Most Recent Events

  • 28 Aug 2019 No recent reports on development identified - Phase-III for Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in Japan (PO)
  • 28 Aug 2019 No recent reports on development identified - Phase-III for Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in South Korea (PO)
  • 28 Aug 2019 No recent reports on development identified - Phase-III for Partial epilepsies (In adolescents, In adults, Monotherapy, Newly diagnosed, Recurrent) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top